The new Biotech and Biomanufacturing Hub, a key milestone in the European Commission’s Strategy to boost biotechnology and biomanufacturing in the EU, was officially launched on 30 January 2025. Designed as a central reference point, the Hub is accessible through the Your Europe web portal and aims to streamline the scale-up process while making it easier for businesses – particularly startups and SMEs – to navigate complex regulatory frameworks.
Companies looking to bring innovative biotech products to the EU market and enhance their competitiveness can access a comprehensive set of resources within the Hub. The platform provides essential information on regulatory pathways for human and veterinary medicines, biologicals, advanced therapy medicinal products (ATMPs), and feed and food ingredients. Additionally, it offers guidance on the authorisation process for different biotech products, intellectual property protection, and health technology assessments—all of which are crucial for ensuring market access and compliance.
Beyond regulatory insights, the Hub also serves as a gateway to EU funding opportunities, helping biotech and biomanufacturing companies identify financial support mechanisms tailored to their needs. A dedicated section highlights available research infrastructures, including pilot and testing facilities, networks, and collaborations that can support R&D and innovation activities. Moreover, companies can leverage market insights provided through the platform to make informed strategic decisions.
By consolidating all these resources into a single access point, the new Biotech and Biomanufacturing Hub represents a significant step toward fostering a more dynamic, competitive, and innovation-driven biotech sector in Europe.
On 11 February 2025, European Commission President Ursula von der Leyen unveiled the new InvestAI initiative at the Artificial Intelligence (AI) Action Summit in Paris. This ambitious program aims to mobilize €200 billion in investments dedicated to advancing artificial intelligence across the European Union. A key component of the initiative is the EU’s InvestAI fund, which will allocate €20 billion to finance the construction of four new AI gigafactories across the continent. Each of these cutting-edge facilities will house around 100,000 next-generation AI chips and will be specialized in training the most advanced, large-scale AI models.
According to the European Commission, these gigafactories will constitute the world’s most significant public-private partnership in the AI sector, positioning Europe as a leader in the development of trustworthy artificial intelligence. The initiative aligns with the EU’s cooperative and open innovation model, prioritizing complex industrial and mission-critical applications. This announcement follows the initial plan for seven AI factories, which was unveiled in December 2024, with an additional five expected to be introduced in the near future.
InvestAI will also establish a layered investment fund, offering different risk and return profiles to attract a diverse range of investors. The European Commission’s initial financial contributions will be drawn from existing EU funding programs that include a digital component, such as the Digital Europe Programme, Horizon Europe, and InvestEU.
In addition to these efforts, the Commission will launch a European AI Research Council to consolidate resources and explore innovative ways to leverage data for AI and other emerging technologies. Furthermore, 2025 will see the introduction of the “Apply AI” initiative, designed to accelerate the adoption of artificial intelligence across key industrial sectors, reinforcing Europe’s competitive position in the global AI landscape.
After years of negotiations, Switzerland and the European Union have reached a long-awaited agreement that will see the country participate in key EU research and innovation (R&I) initiatives. The discussions, which aimed to update trade relations across twelve different sectors, concluded on 20 December 2024. The formal signing of the agreements is expected in 2025, followed by a national consultation phase in Switzerland, with the Swiss Parliament set to express its opinion by 2026.
One of the most significant outcomes of this deal is the reintegration of Swiss researchers into EU R&D programmes, including Horizon Europe (all Pillars), Euratom Research & Training, and Digital Europe. Swiss institutions and researchers will be eligible to apply for most funding calls as early as 1 January 2025, thanks to a transitional arrangement established between the two parties. This development restores Switzerland’s role as a key player in European scientific collaboration, strengthening partnerships with institutions across the EU. Beyond research, the agreement also includes a financial contribution from Switzerland to the EU’s cohesion fund, amounting to CHF 130 million per year from 2025 to 2029. These funds will be directly allocated to programmes and projects in EU partner countries, reinforcing Switzerland’s commitment to European economic and scientific cooperation.
Additionally, the negotiations have resulted in an updated health agreement, expanding Switzerland’s involvement in European health security frameworks. The country is now set to participate in the EU’s health security mechanisms and the European Centre for Disease Prevention and Control (ECDC), ensuring closer collaboration in areas such as pandemic preparedness, disease monitoring, and crisis response. With these agreements, Switzerland is taking a crucial step towards deeper integration with the EU’s research, digital, and health ecosystems, fostering stronger ties with European partners and reinforcing its position as a hub for scientific and technological excellence.
Digital trust is crucial in modern cybersecurity, defined as users’ confidence in the ability of people, technology, and processes to create a secure digital environment.[1] It mirrors patients’ essential trust in pharmaceuticals; both scenarios involve an intrinsic relationship where the end user relies on a product’s safety, efficacy, and reliability. This parallel underscores a universal truth: trust is a vital currency in any sector where the consumer has limited visibility into the processes, whether it involves medications or technological services. In the pharmaceutical industry, trust is built over time through painstaking research, regulatory compliance, clinical trials, and ongoing evaluation through pharmacovigilance, all designed to assure patients and providers of a drug’s safety and effectiveness. Similarly, in IT services, particularly cybersecurity, trust hinges on best practices, transparent processes, and verifiable outcomes.
The CrowdStrike incident: a case study
The CrowdStrike incident on July 19, 2024, provides a poignant case study highlighting the crucial need for digital trust. An update to the Falcon sensor application led to widespread outages, impacting approximately 8.5 million Windows machines due to a substantial coding error. The responses post-incident unveiled vital factors that contributed to the outage: a flaw in a content validation process and the failure of specific testing protocols that could have identified the potential vulnerability.[2] The dynamics of the events resembled the Swiss cheese model of accident causation.[3] CrowdStrike’s response to the incident – committing to enhanced software testing and adopting a staggered deployment strategy – reflects approaches commonly employed in the pharmaceutical industry. As pharmaceutical manufacturers routinely revisit and refine their quality assurance processes, software vendors must continuously improve their development and release processes.
Lessons learned and recommendations
A key takeaway from the CrowdStrike incident is the risk associated with automated updates, which, although crucial for efficiency and maximum protection, can result in widespread failures. Cybersecurity solutions vendors should prioritize software testing processes to mitigate future incidents, emphasizing the importance of extensive and exhaustive code testing before deployment. Moreover, effective communication strategies are vital to maintain transparency during IT incidents. The CrowdStrike outage spotlighted organizations’ need to provide clear directions regarding the incident’s cause, immediate remediation actions, and preventive measures moving forward. Drawing parallels with the pharmaceutical industry, organizations must also foster a culture of accountability, demand adherence to ethical practices, and demonstrate a proactive stance toward the quality of processes and products. Building digital trust through more effective software testing or responsive communications is imperative for long-term success in today’s digital-centric marketplace.
In a post published on the association’s blog and signed by Alexander Olbrechts, director Digital Health, MedTech Europe turned the spotlight back on the possible impact of the AI Act, the new European legislation that aims to regulate the safety and quality aspects of artificial intelligence applications. An area that is presented to offer numerous opportunities in the field of medical technologies as well, side by side with just as many challenges in how to implement them.
First and foremost is the need to integrate the new provisions of the AI Act with what is provided by existing industry legislation, most notably the Medical Devices Regulation (MDR) and the In Vitro Diagnostics Regulation (IVDR). MedTech Europe’s goal here is to continue the dialogue with European legislators to ensure that the two strands of legislation actually complement each other, avoiding duplication of activities or conflict with procedures already in place.
One of the main goals of the AI Act, moreover, is to arrive at a smoothly flowing compliance process for AI-enabled medical technologies. A goal that, according to Olbrecht, should involve aligning compliance assessment with what is already in place in the MDR and IVDR regulations. The suggestion here is to maintain the existing technology codes for notifications to authorities and notified bodies, to which is added the possibility of assisting sectoral notified bodies with designation procedures under the AI Act, avoiding delays.
The MDR and IVDR regulations also introduced a strong component of clinical investigations and studies on device performance to support their efficacy and safety. According to Medtech Europe, the AI Act should serve as a facilitator in this regard, and a specific priority clause should be provided for the MDR and IVDR regulations in case of conflict with the provisions of the new AI legislation. MedTech Europe’s request is that it be definitively clarified that clinical and performance evaluations should be considered exempt from any requirement for CE certification under the AI Act, and thus continue to follow the pre-market testing rationale established of two medical device and in vitro diagnostic regulations.
Finally, there is no shortage of mention of the development of new digital therapies, in which AI models and data analytics play a key role in the development, for example, of innovative diagnostic solutions that can reduce the need for hospitalization.
An information note agreed between the European regulatory authorities and AIFA (the Italian medicines agency) reports the results of a retrospective study, according to which the risk of venous thromboembolism (VTE) is slightly increased in women using combined hormonal contraceptives based on chlormadinone acetate and ethinylestradiol.
The conclusion comes from the retrospective cohort study RIVETRCS, according to which the risk of venous thromboembolism increases 1.25-fold with this type of contraceptive compared to women taking combined hormonal contraceptives containing levonorgestrel. Based on these results, the annual risk of VTE in women taking chlormadinone acetate with ethinylestradiol is estimated at 6-9 cases of VTE per 10,000 women.
These data are compared with an annual incidence of 5-7 VTE cases per 10,000 women using low risk combined hormonal contraceptives containing levonorgestrel, norethisterone or norgestimate, and with 2 VTE cases per 10,000 women not using a combined hormonal contraceptive.
The decision to prescribe a combined hormonal contraceptive must therefore take into account the individual woman’s risk factors for VTE and be based on a comparison with the VTE risk of other combined hormonal contraceptives. AIFA also points out that the risk is highest during the first year of use of any combined hormonal contraceptive or upon resumption of treatment with combined hormonal contraceptives after a break of 4 weeks or more.
Quality Culture has evolved into a critical component for biopharma and medical device companies since it was initially established in the early 2000s, when both regulatory agencies and industry were focused on increasing quality throughout the entire life cycle of product development. It has become clear that, whatever an employee’s position is – from technician to C suite executive – every department of the company should be built around quality so that the end goal is to ultimately provide the end-user – the patient – a quality drug or medical product.
Over the past 10-20 years, companies have developed the work required to develop a Quality Culture; some have accomplished this, but some have not. Initiatives taken to advance towards Quality Culture include working on regulatory deficiencies and all issues that can trigger the receipt of FDA warning letters; these initiatives require hard work to actually equate all work done to true Quality Culture. Everyone in the organization must be fully knowledgeable about quality; the quality concept must be instilled as a critical requirement in their jobs.
In addition to ensuring training and educating all employees on the importance of Quality Culture, another challenge, especially for older companies, is bringing their facilities thoroughly up-to-date, including equipment, computer and document management systems, digitalization, etc.; that can be costly and time-consuming. New facilities and those being planned should focus particularly on current and future trends, equipment, and digital capabilities.
For a solid 25 years, PQE Group has been tackling these challenges head-on. But this year, they’re stepping up their game with some slick docu-videos delving into the vital realm of Quality Culture. Picture this: shining a spotlight on everyday heroes – patients leading ‘normal’ lives, courtesy of cutting-edge meds and devices. Prepare to uncover the origin story of the ‘Q’ factor straight from the company DNA, revealing why it’s an absolute game-changer.
The question to you, reader, at this point is: Does your Company have the “Q factor”? Find the answer through the story of :
Eva – “Veterinarians: Ensuring Quality Care for Animals”
Eva, a Tuscan veterinarian, has a special bond with pets and livestock. Her work is a source of love and fulfillment, but it also carries great responsibility: identifying diseases and conditions and ensuring the administration of correct and high-quality medication. For animals as well, the Quality Culture intrinsic to the medication they take is invaluable.
Alessandro – “Learning to Hear at 30” –
Alessandro has recently emerged from a world of silence, thanks to a cutting-edge cochlear implant. We’ll delve into how top-tier medical devices, like Alessandro’s implant, can profoundly enhance patients’ lives. The documentary highlights the vital role of quality culture within companies to guarantee dependable and impactful products. It showcases the fusion of technology and corporate dedication in delivering transformative medical solutions. Join us on this journey celebrating hope, progress, and the imperative of investing in innovation for a better tomorrow.
Elisabetta: “Elevating Hope: Advocating for Cannabinoid Therapy”
Elisabetta is an amazing Italian woman affected by several pathologies, including Arnold Chiari, Ataxia, and Small Fiber Neuropathy, which cause chronic pain, tremors, and severe headaches. Having experienced significant benefits from using medical cannabis, she has long been advocating for institutions to recognize the importance of cannabinoid therapy. It’s crucial to highlight the significance of managing medical cannabis across all stages and ensuring Quality Culture to deliver the best possible product for patients.
Be sure to visit PQE Group’s Quality Culture page to view these informative, and important, videos to stay on top of new and exciting industry developments that utilize Quality Culture clicking on the QR Code here below!
In an area covering almost 1,400 sqm, the Pharmaceutical Divisions of IMA Group and its specialists are glad to introduce IMA Pharma, the All-In-One supplier specialized in the design and manufacture of innovative machines and complete lines for the processing and packaging of pharmaceutical and nutraceutical products, medical devices assembling, as well as projects concerning digitalisation, sustainability, and customer service solutions.
Meeting the Divisions at the show
IMA Active is the ideal partner for each solid dose processing phase: granulation, tableting, capsule filling and banding, weight checking, coating, handling and washing. On show AQUARIA, the new all-in-one solution to wash components and machine parts of different sizes and volumes in completely automatic mode, ensuring greater efficiency and respect for the environment; the Continuous Direct Compression Line (CDC Line), a very lean, efficient and flexible tablet-manufacturing technology that, in combination with PAT, allows easy adoption of a QbD approach, ensuring excellent operation performance and avoiding waste during startup and shutdown; the CROMA continuous coater, designed to cover a range of throughputs and a range of coating weight gains thanks to its innate modularity; a single CROMA module works in ranges between 20 and 100 kg/h and with an average weight gain of 2-4%, depending on tablets and film types; the ADAPTA 50 capsule filler, featuring innovative technical solutions to manage complex solid dosage forms such as product combination in hard gelatine capsules or powder micro-dosing for Dry Powder Inhalers. The ACCELA CTC 500 continuous coater by Thomas Processing is designed to manage high production throughputs in a range of 100-1,000 kg/h of large batch sizes of tablets to process in continuous mode, being the only coater on the market manufactured with an integrated cooling chamber that eliminates the need for additional cooling systems, reducing the footprint of the equipment and streamlining the coating process. On show also the IMA Active Competence Center, a specialised and centralised hub for knowledge and resources, providing support, training, and guidance in the oral solid dose field.
IMA Life offers a comprehensive product portfolio to process liquids and powders in aseptic and non-aseptic environments. Solutions include washers, depyrogenating tunnels, liquid and powder filling and closing machines for vials, ampoules and Ready-To-Use (RTU), freeze dryers and relevant automatic loaders/unloaders, isolation technologies, labellers for vials and cartons and ancillary equipment. On show, the integrated line composed by NEBULA, the high speed-decontamination tunnel which integrates seamlessly with IMA Life aseptic fill-finish lines, ensuring 100% sterility of RTU material and INJECTA 36, advanced robotic fill-finish solution which raises the bar for the high-speed processing of RTU syringes. Introducing an innovative solution for 100% In-Process Control and check-weighting, INJECTA 36 is further proof of the key role played by IMA Life in the Ready-To-Use segment for automatic filling & closing machines, able to maximise production performance. In a segregated area of the booth, you will be able to discover in world premiere TILE-X, IMA Life’s ground-breaking innovation in the field of fill-finish processing for small batch production. Based on electromagnetic levitation, TILE-X is a compact, Grade A, gloveless modular processing unit for high-value pharmaceuticals such as ATMPs. Also on show, MODULA 300, the assembly machine for pre-filled glass syringes capable of performing several operations: plunger rod insertion, labelling, backstop assembly, and a dedicated hub for isolation technology. Our aseptic processing experts will introduce you our isolation solutions: highly configurable, they adapt to different production environments, enhancing versatility and applicability to different manufacturing contexts including high-containment scenarios. At the LAB4LIFE Lyo development Laboratory corner, IMA Life’s experts will present KryoAir, our new 100% green refrigeration technology for freeze dryers using the ultimate natural refrigerant: air.
Along with the equipment displayed at the fair, customers will have the opportunity to experience firsthand various digital solutions aimed at reducing maintenance costs and downtime. These solutions leverage real-time monitoring, event forecasting, and fault prevention through the analysis of vast amounts of process and equipment data, ultimately leading to an increase in overall equipment effectiveness and compliance with current regulations.Along with the equipment displayed at the fair, customers will have the opportunity to experience firsthand various digital solutions aimed at reducing maintenance costs and downtime. These solutions leverage real-time monitoring, event forecasting, and fault prevention through the analysis of vast amounts of process and equipment data, ultimately leading to an increase in overall equipment effectiveness and compliance with current regulations.
GIANT5-A96
Specialised in primary and secondary packaging, IMA Safe creates blister-packaging machines, capsule and tablet counters, sachet and stick-packaging machines, tube fillers and cartoners. End-of-line solutions, from robotics, handling, overwrapping to case-packing and palletizing are provided by the IMA EOL hub. On show the GIANT5-A96 integrated blister and cartoning line, which redefines the parameters in terms of flexibility, speed and compactness; the RED250-A96 deep draw thermoforming and cartoning line, a compact solution for medium-speed production of small batches requiring frequent format changes. Thanks to the robotic handling system, RED250 allows careful and precise manipulation of any type of product, introducing it into the tray with a wide range of possible configurations; the MINILINE bottle transport, filling and capping system able to integrate all the functions required to form a complete counting line with a simple and superior footprint: desiccant insertion, tablet or capsule counting, cotton insertion and capping, and can be configured for any product or container requirement and BETA 360 a high-performance vertical sachet packaging machines for 4-seal sachets, able to handle all types of products from paste products to fluid products, powders, free and non-free-flowing products, objects and accessories such as wipes.
The End of Line Hub’s experts will be also present to discuss and highlight the latest solutions available from IMA, completing the line. These include a wide range of options, from bundling and wrapping machines, case packers, palletizers and depalletizers, to state-of-the art, integrated systems featuring robotic solutions for enhanced flexibility and efficiency.
IMA AUTOMATION designs and manufactures advanced technological systems for the handling and assembly of a variety of components for diverse applications and in different sectors: automotive, E-mobility, electrical motors, medical devices, caps & closures, eye care, electro-mechanics and watchmaking. On show the X-PEN, the standard modular platform for pen and autoinjector final assembly. With the latest robust technologies, labelling as standard incorporated into the machine, quick time-to-market and compact design concept, the X-PEN system uses state-of-the-art, at your fingertips technology and ensures fast ROI.
Visitors will also have the chance to discover dedicated areas covering hot topics like Sustainability, Digitalisation and Customer Service Solutions.
Our specialists will be glad to provide with an overview of the initiatives we conduct to improve sustainability, including our OPENLab network where we develop and test the latest eco-friendly packaging materials alongside our customers.
IMA will showcase a diverse array of digital tools and virtual applications, beginning with machines equipped with IMA Sentinel connectivity. This will include a comprehensive suite of Artificial Intelligence solutions such as Sandbox and Algomarket, enhanced by advanced analytics. The event will also offer an opportunity to present IMA’s latest proof-of-concept in generative artificial intelligence, aimed at improving training, troubleshooting, and monitoring activities.
Additionally, targeted services like training opportunities, troubleshooting support, and a broad range of platforms for machine management will be highlighted, including the customer service portal, services provided globally to the pharmaceutical industry to maintain the highest production standards.
An Industry 4.0 control platform is made up of a complex architecture that integrates the functions of the different systemsincluded within it.
The Hazel® smart environment-control platform, for example, while enabling the integration of different systems according to user-defined rules and permitting their management through a web based software – also from mobiles equipped with a dedicated app – contains several devices that can also be operated as autonomous elements, such as the wall clock Hazel® Tempus.
This industrial clock has been specifically designed by Dos & Donts to be used in sterile manufacturing facilities– but it also proves useful in other industrial and non-industrial work environments – and it can be supplied and used independently from the integrated platform.
High precision to comply with pharmaceutical requirements
The need for the pharmaceutical industry to close each production batch filling out a Batch record compliant to GMP rules requires a strict control of exact times along the entire manufacturing process, with monitoring of all its phases and cycles. The Batch record contains detailed information on the time of starting and ending of the production, and other information describing each single passage of the industrial process, e.g. temperatures and concentrations and all the different materials and intermediates used for it. The signature of the Batch record by the in-charged person goes together with documenting also the specific date and time.
To meet the GMP’s requirements, a precise and synchronized time indication through all manufacturing departments is needed.In the Industry 4.0 architecture, this demand has been catched up by Dos&Donts by proposingHazel® Tempus,a wall clock developed according to the new paradigms and specifically studied to be placed into clean rooms.
The clock can be freely integrated with smart systems different than Hazel®, and can receive inputs and exchange informationallowingfor the carrying out of actions at specific time viathe TCP/RTU Modbus protocol. Time synchronization across the clocks present in the different manufacturing units, as well as across the different equipment’s and devices operating along the production chain, is provided by connecting to a NTP server or to a BMS via TCP/RTU Modbus.
The time indicated by Hazel Tempus is clearly visible at each moment to operators thanks to its wide and bright LED 4-digit display. Offering an input and an output, the wall clock also provides actuations functionalities, that can be activated or disabled by a pre-defined time schedule or upon achievement of a specific event .
Furthermore, the auxiliary serial connection allows to use the wall clock in conjunction with otherdevices, for example a printer to print out start and ending of a specific operation
The technical characteristics
Hazel® Tempus is characterised by a very thin layout (just 41 mm) and can be easily installed into the wall; its stainless steel structure houses a coplanar display, creating a completely flushstructure highly resistant to common sanitizing agents used in clean rooms, and making the wall clock ideal to be used within controlled contamination environments.
Once placed on the wall and connected to the facility’s LAN network, connection to Hazel® Tempus through a specific interface enables the necessary configurations setting.
Hazel® Tempus can be poweredPoE or 24Vdc; it can provide an alarm in case of synchronization fail with the NTP server. Thanks to the internal battery, the current time is not lost even in case of power fail. Four different alerts are available, which can be pre-set at established times in order to automatically activate – for instance – lights, fans, acoustic alarms or send a signal on Modbus.
If integrated with other systems, Hazel® Tempus allows to activate specific actions – i.e. video recording, emission of light or sound signals, opening of interlocked doors, etc. – upon the achievement of a pre-determined time or event.
The keywords of the third millenium are digitalisation and interconnectivity: the new paradigm of automation is based on the wide availability of data from digitally integrated systems allowing for greater traceability, flexibility, adaptability and efficiency of the smart factory. Pharma 4.0 reference model of vertical and horizontal integration relies on enabling tecnologies such as IoT, augmented reality, additive manufacturing, simulation, data analytics, cloud computing, smart robots,cyber security.
In a holistic approach, these technologies can be profitably applied not only to the Pharma process but also to the production environment, where different control systemsinteract between them and with the process.
Many different modules for Environment controls
Diverse environment controls are required in Pharmaceutical manufacturing to grant the compliance to GMP standards and to support optimized product quality, especially in the strictly regulated cleanroom environment.
This includes controls to be put in place to match the sometimes conflicting needs ofproduction quality (GMP) and personnel safety (HSE) as for instance at the level of operated doors, interlocks, personnel access, doors interaction with AGVs, critical environmental parameters, communication between areas.
All these systems can be interconnected between them providing data alarms andprompt information on any anomalous situation affecting production or operator safety. Under the Industry 4.0 approach, an environment control platform should be able tocommunicate using technologies such as Lan and IoT, to easily integrate with building systems (i.e. Scada and Dc systems). Data can be collected, logged and managed in compliance with CFR21 Part 11 requirements, cloud data storage can be profitably used for integration with other platforms.
A complete, and open, multi-layer platform
This approach requires the availability of platforms to host and operate the different functions and controls. An example in the field of environment control is the Hazel® multi-layer platform developed by Dos & Donts: each of its small intelligent modules is dedicated to a specific function and is able to communicate with the others through WiFi/Lan connections. The final result are “tailor-made” complete and easy scalable systems that can be designed to reflect all different applicative needs, simply plugging together multiple basic units to form increasingly complex systems. Hazel® is also an “open” platform, as additional systems can be integrated at all times. The modular approach also provide benefits to reduce the hidden costs for installation, management and maintenance.
A user-friendly MMI
The interaction between the different units can be regulated by user-defined rules; easy of use is increased by the possibility to set the units working parameters using a mobile device equipped with the dedicated App.
All data collected by each unit are real time transferred to the dedicated webserver unit Hazel® core, equipped with “Sigma”, a web based software which provides the data log and allows for real-time monitoring, statistics elaboration, triggers and interaction rules among connected units while operating as “system manager”. Data stored into the webserver are readily available to the BMS via a Tcp Rtu Modbus interface; in alternative, data can also be
accessed through the dedicated Hazel® cloud portal. Data security is safeguarded by the use of encryption protocols.
Smart bricks to personalise the systems
Each different industrial plant has its own, specific needs as for Environment control, that should be captured and reflected by the architecture of the control systems (see figure).
Each different function is managed by a specific “smart brick”, which can work autonomously or can be connected to the Hazel® core server.
Among the smart bricks Hazel® Visio, a touch screen Led display, and Hazel® Aditum, an access control reader, both specifically designed for cleanroom environments. Motion within the cleanroom can be monitored using the Hazel® Moveo smart cam, while the combination of different modules of the Hazel® Janus smart door controller permits to create powerful and flexible door interlock systems. Hazel® Acta I/O smart interface can convert digital I/Os to be transmitted on a Tcp or WiFi data line. It can be used to collect data from sensors and to drive outputs according to defined specifications. The I/O controller provides an acoustic signal for local event notification.
The Hazel® platform easily integrates with many other Dos & Donts systems, i.e. the Ilock M16 panel that can manage from one to twelve interlocked doors, and the Multigates 12 web-based access control software for cleanroom
